Alexion $ALXN announced fiscal third quarter results. Total revenue for the recently concluded quarter was $799 million, a 20% increase Y-o-Y. Volume jumped 23% Y-o-Y. Actual sales beat the consensus estimate by $12.25 million. EPS was $1.23, beating estimate by $0.06. Soliris� (eculizumab) revenue growth was driven by steady number of new patients with PNH and aHUS Traeted globally. The company during the earnings call also said that Robust Strensiq��(asfotase alfa) launch has progressed with new patients starting on treatment adding that Kanuma��(sebelipase alfa) launch has continued with new patients treated in initial Countries. The drug-maker will file regulatory submissions for Eculizumab for the treatment of patients with Refractory gMG in both the U.S. and Europe in the first quarter of 2017.